Considering the fact that tumor infiltration of CD8+ T cell is vastly limited [15], thus BC has been clinically considered poor immune-responsive or immunologically “cold” [16] and patients who are suffering from metastatic BC have a particularly low ORR to ICB therapy, only from 3 to 21% [17]. This evidence concerns the gene CD8A and breast cancer.